Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Immune checkpoint inhibitors

6 evidence topics · 4 sources

MSI-H or dMMR solid tumors: objective response in prostate cancer
Tumor typePatientsObjective response, n (%)95% CIDuration of response, months
Prostate cancer“8”“1 (13%)”“(0%, 53%)”“24.5+”